Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.53B | 52.94B | 46.58B | 44.25B | 37.11B | 29.27B |
| Gross Profit | 44.00B | 39.70B | 34.45B | 28.04B | 22.60B | 21.66B |
| EBITDA | 19.75B | 14.86B | 13.20B | 8.63B | 4.59B | 8.04B |
| Net Income | 9.51B | 6.89B | 6.06B | 3.28B | 109.85M | 3.39B |
Balance Sheet | ||||||
| Total Assets | 114.46B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B |
| Cash, Cash Equivalents and Short-Term Investments | 8.18B | 5.65B | 5.91B | 6.24B | 6.37B | 7.95B |
| Total Debt | 32.66B | 30.11B | 28.41B | 29.14B | 30.69B | 20.38B |
| Total Liabilities | 68.48B | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B |
| Stockholders Equity | 45.89B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
Cash Flow | ||||||
| Free Cash Flow | 11.15B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B |
| Operating Cash Flow | 15.14B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B |
| Investing Cash Flow | -6.54B | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M |
| Financing Cash Flow | -4.93B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £222.43B | 30.89 | 22.34% | 1.53% | 10.20% | 40.57% | |
77 Outperform | £75.86B | 13.90 | 36.44% | 3.29% | 2.73% | 119.38% | |
75 Outperform | £3.45B | 12.09 | 15.66% | 4.16% | 3.73% | 27.13% | |
70 Outperform | £10.31B | 27.96 | 9.30% | 2.35% | 2.51% | 56.56% | |
68 Neutral | £4.59B | 28.74 | 12.73% | 2.11% | 4.18% | 37.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
AstraZeneca Corporate Events
AstraZeneca has appointed Joris Silon as Head of Investor Relations, effective 1 March 2026, succeeding Andy Barnett and based in Cambridge, UK. Silon moves into the role from his position as country president of AstraZeneca US, where he oversaw significant growth in the company’s largest market, bringing more than two decades of global leadership experience across Asia, Europe and the US. The appointment underscores AstraZeneca’s focus on strengthening its engagement with the investment community as it enters a new phase of growth, while Barnett transitions to another senior role within the company, maintaining continuity in its investor relations strategy and leadership.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting rights consists of 1,550,907,927 ordinary shares, with no shares held in treasury, establishing the total number of voting rights at the same figure. This disclosure, made under UK Financial Conduct Authority transparency rules, provides shareholders and market participants with the reference denominator needed to assess and report any holdings or changes in holdings, supporting regulatory compliance and ensuring clarity around AstraZeneca’s equity base and governance structure.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca disclosed that non-executive director Nazneen Rahman sold 297 ordinary shares in the company at a price of £134.96 per share on 18 December 2025, in a transaction carried out on the London market and reported under UK market abuse regulations. The relatively small director share sale is a routine governance disclosure rather than a signal of a strategic shift, but it nonetheless provides transparency for investors monitoring insider dealings in one of the UK’s largest biopharmaceutical groups.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Daiichi Sankyo’s HER2-directed antibody drug conjugate Enhertu has received US FDA Breakthrough Therapy Designation as a post‑neoadjuvant treatment for adults with HER2‑positive early breast cancer who have residual invasive disease and a high risk of recurrence after initial therapy. The designation, based on positive Phase III DESTINY‑Breast05 data showing superior outcomes versus current standard T‑DM1, marks the drug’s tenth such status and underscores its potential to reshape care in early‑stage, high‑risk HER2‑positive disease, complementing an expanding label that already spans multiple metastatic breast, lung, gastric and solid tumour indications and reinforcing AstraZeneca’s and Daiichi Sankyo’s competitive leadership in the fast‑growing ADC oncology market.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca reported that its Phase III LATIFY trial testing the ATR inhibitor ceralasertib in combination with its immunotherapy Imfinzi in patients with previously treated, locally advanced or metastatic non-small cell lung cancer failed to meet its primary endpoint of improving overall survival compared with standard chemotherapy agent docetaxel. The company said the combination was generally well tolerated with no new safety signals and confirmed that full data will be shared at an upcoming medical meeting, underscoring both the challenges of extending immunotherapy benefits in heavily pre-treated lung cancer patients and AstraZeneca’s continued strategic emphasis on novel oncology combinations despite this setback.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has disclosed an internal share transfer involving Non-Executive Director and PDMR Philip Broadley, who gifted 5,735 ordinary shares in the company to his spouse, Gillian Broadley, for no consideration on 17 December 2025. The off-market transaction, notified in line with UK Market Abuse Regulation requirements, represents a reallocation of shares within a closely associated person group rather than a change in overall insider ownership, and is primarily relevant for transparency and compliance purposes rather than signalling any shift in the company’s strategic or financial outlook.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Saphnelo has been approved by the European Union for subcutaneous self-administration as a pre-filled pen for treating systemic lupus erythematosus (SLE), providing a more convenient option for patients. This approval is based on positive results from the Phase III TULIP-SC trial, which demonstrated significant reductions in disease activity. The new administration method is expected to expand patient access and choice, enhancing treatment flexibility and potentially improving outcomes for those affected by this debilitating autoimmune disease.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved in the US for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. This approval, based on the DESTINY-Breast09 Phase III trial results, marks the first new treatment in over a decade to show a significant improvement in progression-free survival over the current standard regimen. The combination therapy reduced the risk of disease progression or death by 44% and extended median progression-free survival to over three years. This development is expected to set a new standard of care and has significant implications for improving long-term outcomes for patients with HER2-positive metastatic breast cancer.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca PLC announced that as of November 30, 2025, its issued share capital with voting rights consists of 1,550,725,869 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s rules, which could impact shareholder engagement and transparency in the company’s governance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as the first perioperative immunotherapy for early-stage gastric and gastroesophageal junction cancers, based on the MATTERHORN Phase III trial results. This approval, which follows a Priority Review by the FDA, marks a significant advancement in the treatment of these cancers, offering a new standard of care with a notable survival benefit. The Imfinzi regimen, combined with FLOT chemotherapy, demonstrated a 29% reduction in disease progression risk and a 22% reduction in death risk compared to chemotherapy alone, establishing a new clinical paradigm and providing renewed hope for patients.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced a $2 billion investment to expand its manufacturing operations in Maryland, which will support 2,600 jobs and boost economic growth. This expansion includes enhancing its biologics manufacturing facility in Frederick and building a new state-of-the-art facility in Gaithersburg, both of which will be operational by 2029. The move is part of AstraZeneca’s broader $50 billion commitment to medicines manufacturing and R&D, aimed at strengthening the US medicine supply chain and accelerating access to transformative therapies.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £18400.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Koselugo (selumetinib) has been approved by the US FDA for treating adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), based on positive results from the KOMET Phase III trial. This approval marks a significant advancement in treatment options for adults with NF1, building on Koselugo’s established use in pediatric patients, and is expected to enhance AstraZeneca’s position in the rare disease market while providing continuity of care for NF1 patients.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £18400.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced a transaction involving the sale of 15,000 American Depositary Shares by Aradhana Sarin, the company’s Executive Director and Chief Financial Officer, at a price of $88.6345 per share. This transaction, disclosed in accordance with EU Market Abuse Regulation, may have implications for stakeholders as it reflects executive-level financial decisions within the company.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £184.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that its CEO, Pascal Soriot, has gifted 136,537 ordinary shares of the company to family members without any financial consideration. This transaction was conducted outside a trading venue and aligns with the regulatory requirements of the EU Market Abuse Regulation, reflecting transparency in executive shareholding activities.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca reported strong financial performance for the first nine months of 2025, with total revenue increasing by 11% to $43.2 billion, driven by growth in all therapy areas, especially oncology. The company achieved 16 positive Phase III trial readouts and 31 major approvals, reinforcing its pipeline strength. AstraZeneca is also expanding its operations in the US, including a $4.5 billion manufacturing facility in Virginia, and has reached a historic agreement with the US government to lower drug costs, which is expected to enhance its market positioning and stakeholder relations.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced that its shareholders have approved a resolution to adopt new articles of association, facilitating the harmonization of its equity listing structure across London, Stockholm, and New York. This move is expected to provide AstraZeneca with greater flexibility to access a broader pool of capital, particularly in the US, and reflects strong shareholder support. The new structure is anticipated to enhance AstraZeneca’s market presence and investment opportunities as it continues to expand in its growing markets.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced that as of 31 October 2025, its issued share capital with voting rights consists of 1,550,712,906 ordinary shares, with none held in Treasury. This figure is crucial for shareholders to determine their notification obligations under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and regulatory compliance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Koselugo (selumetinib) has been approved in the EU for treating symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1), based on the KOMET Phase III trial results. This approval marks a significant advancement in the treatment landscape for NF1, extending the benefits of Koselugo from pediatric to adult patients, and highlights AstraZeneca’s commitment to addressing unmet needs in the rare disease community.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £15000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca, in collaboration with Amgen, announced the European Union approval of Tezspire (tezepelumab) for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults who have not responded to standard therapies. This approval, based on the successful results of the WAYPOINT Phase III trial, marks a significant advancement in treatment options for CRSwNP, potentially reducing the need for surgery and systemic corticosteroids, and reinforcing AstraZeneca’s position in addressing epithelial-driven inflammation.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £145.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca and Amgen’s Tezspire has been approved by the US FDA for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), expanding its indications beyond severe asthma. This approval, based on the successful results of the WAYPOINT Phase III trial, positions Tezspire as a novel treatment option that significantly reduces the need for surgeries and systemic corticosteroid use, offering relief to millions affected by this condition. The approval is expected to enhance AstraZeneca’s market position in respiratory and immunology, reflecting its commitment to transforming patient care in chronic respiratory and immune-mediated diseases.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £137.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Saphnelo (anifrolumab) has been recommended for approval in the EU for self-administration via a pre-filled pen for adult patients with systemic lupus erythematosus (SLE). This recommendation by the CHMP is based on the TULIP-SC Phase III trial results, which demonstrated a significant reduction in disease activity. The approval could enhance patient access to Saphnelo, offering a convenient once-weekly option that aligns with updated treatment guidelines emphasizing reduced steroid use. This development positions AstraZeneca to further expand its presence in the autoimmune disease treatment market, potentially benefiting stakeholders by addressing unmet needs in SLE management.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £137.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced a historic agreement with the US Government to lower prescription medicine costs for American patients, aligning prices with those in wealthy countries. This agreement includes a $50 billion investment in US manufacturing and R&D, supporting domestic sourcing and innovation, and aims to generate $80 billion in revenue by 2030. The initiative also involves AstraZeneca’s participation in the TrumpRx.gov platform for discounted direct-to-consumer sales and a delay in Section 232 tariffs, enhancing the company’s US operations and economic contributions.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.